Skip to main content
. 2024 Mar 8;15:1347361. doi: 10.3389/fneur.2024.1347361

Table 3.

HBOT, HBAT and HBT in children with CP, 8 groups, n = 316.

References Treatments n Age (months) Treatment duration (months) GMFM initial (%) GMFM final (%) Gain GMFM ENE GMFMER
Collet et al. 2001 (62) HBOT-1.75ATA 57 86.4 2.0 57.3 60.2 2.9 0.1 36.3
Mukherjee et al. 2014 (43) HBOT-1.75ATA 58 51.6 6.0 32.5 42.1 9.6 0.5 20.9
Mukherjee et al. 2014 (43) HBOT-1.5ATA 32 51.6 6.0 34.3 42.5 8.2 0.5 16.4
Lacey, Stolfi, et Pilati 2012 (11) HBOT-1.5ATA 25 75.6 2.0 39.5 40.7 1.2 0.1 20.0
Montgomery et al. 1999 (63) HBOT-1.75ATA 25 67.2 1.0 56.9 61.6 4.7 0.1 47.0
Mean 66.5 3.4 44.1 49.4 5.3 0.2 28.1
SD 15.2 2.4 12.1 10.5 3.5 0.2 13.0
Collet et al. 2001 (62) HBAT-1.3ATA 54 86.4 2.0 66.3 69.3 3.0 0.1 25.0
Mukherjee et al. 2014 (43) HBAT-1.3ATA 40 58.8 6.0 29.6 38.6 9.0 0.3 34.6
Mean 72.6 4.0 48.0 54.0 6.0 0.2 29.8
SD 19.5 2.8 26.0 21.7 4.2 0.1 6.8
Lacey, Stolfi, et Pilati 2012 (11) HBT-1.5ATA + 14%O2 25 62.5 2.0 40.7 41.8 1.1 0.1 8.5

ENE, expected natural evolution; GMFM, gross motor function measure; GMFMER, gross motor function measure evolution ratio; HBAT, hyperbaric air treatment; HBOT, hyperbaric oxygen treatment; HBT, hyperbaric treatment.